selected scholarly activity
-
chapters
-
conferences
- Late Clinical Outcomes of Diabetic Patients Randomized in the Occluded Artery Trial (OAT). Circulation. S661-S661. 2008
- International patterns in the care of acute myocardial infarction patients in the occluded artery trial (OAT): Characteristics of 1,835 screened patients. Journal of the American College of Cardiology. 377-378. 2003
-
journal articles
- Effect of spirulina on risk of hospitalization among patients with COVID-19: the TOGETHER randomized trial.. American Journal of Clinical Nutrition. 120:602-609. 2024
- Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 10:342-352. 2024
- Mortality and Morbidity in Adults With Rheumatic Heart Disease. Journal of the American Medical Association (JAMA). 332:133-133. 2024
- Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation. New England Journal of Medicine. 391:9-20. 2024
- Matched vs Nonmatched Placebos in a Randomized Trial of COVID-19 Treatments. JAMA network open. 7:e2410335-e2410335. 2024
- REVISE:Re-Evaluating theInhibition ofStressErosions in the ICU: a randomised trial protocol. BMJ Open. 13:e075588-e075588. 2023
- Pegylated Interferon Lambda for Covid-19. New England Journal of Medicine. 388:2107-2108. 2023
- Global Variations in Heart Failure Etiology, Management, and Outcomes. Journal of the American Medical Association (JAMA). 329:1650-1650. 2023
- Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19. ACP journal club. 176:667-675. 2023
-
Hydroxychloroquine for treatment of non‐hospitalized adults with
COVID ‐19: A meta‐analysis of individual participant data of randomized trials. Clinical and Translational Science. 16:524-535. 2023 - Early Treatment with Pegylated Interferon Lambda for Covid-19. New England Journal of Medicine. 388:518-528. 2023
- Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model. American Journal of Tropical Medicine and Hygiene. 108:101-106. 2023
- Ivermectin Treatment for Covid-19. New England Journal of Medicine. 387:e66. 2022
- Toward a New Paradigm of North–South and South–South Partnerships for Pandemic Preparedness: Lessons Learned from COVID-19 and Other Outbreaks. American Journal of Tropical Medicine and Hygiene. 107:1162-1165. 2022
- Correction to Lancet Glob Health 2021; 10: e42–51. The Lancet Global Health. 10:e1246-e1246. 2022
- Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.. Circulation. 146:657-672. 2022
- Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal of Medicine. 386:1721-1731. 2022
- Evaluating COVID-19 vaccines in the real world. The Lancet. 399:1205-1206. 2022
- Fluvoxamine for the treatment of COVID-19 – Author's reply. The Lancet Global Health. 10:e333-e333. 2022
- Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. American Journal of Tropical Medicine and Hygiene. 106:389-393. 2022
- Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial. The Lancet Regional Health - Americas. 6:100142-100142. 2022
- Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet Global Health. 10:e42-e51. 2022
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. The Lancet Diabetes and Endocrinology. 10:35-45. 2022
- Error in Visual Abstract. JAMA network open. 4:e2130442-e2130442. 2021
- Effect of Early Treatment with Fluvoxamine on Risk of Emergency Care and Hospitalization Among Patients with COVID-19: The TOGETHER Randomized Platform Clinical Trial 2021
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology. 78:421-433. 2021
- Three week compared to seven week run-in period length and the assessment of pre-randomization adherence: A study within a trial. Contemporary Clinical Trials. 107:106466-106466. 2021
- How COVID-19 has fundamentally changed clinical research in global health. The Lancet Global Health. 9:e711-e720. 2021
- Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. JAMA network open. 4:e216468-e216468. 2021
- A systematic review of the literature on the relationship between ACE2 and SARS-CoV infection in animal models. University of Toronto Medical Journal. 98:63-68. 2021
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. The Lancet. 396:1895-1904. 2020
- Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19. American Journal of Tropical Medicine and Hygiene. 103:1364-1366. 2020
- Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. American Journal of Medicine. 132:1431-1440.e7. 2019
- Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 140:1578-1589. 2019
- Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation. Cardiovascular Quality and Outcomes. 12:e005858. 2019
- P5522ST elevation myocardial infarction networks: relationship of hub-spoke distance with transfer time and clinical outcomes in rescue PCI. European Heart Journal. 40:ehz746.0470. 2019
- Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal. 40:2801-2809. 2019
- Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. The Lancet. 394:1169-1180. 2019
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes and Endocrinology. 7:618-628. 2019
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 140:103-112. 2019
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 394:121-130. 2019
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet. 394:131-138. 2019
- Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal. 213:35-46. 2019
- Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry. Journal of the American Heart Association. 8:e010510. 2019
- Sharing best practices in applications of evidence-based medicine, problem-based learning and self-directed learning principles in medical training: A McMaster-Brazil collaboration workshop report. MedEdPublish. 8:67-67. 2019
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine. 379:2097-2107. 2018
- Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal. 70:828-835. 2018
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine. 379:1118-1127. 2018
- Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal. 39:464-473. 2018
- Incorporating evidence-based principles in medical training. Sharing experience with McMaster. MedEdPublish. 7:269-269. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:205-218. 2018
- Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:219-229. 2018
- Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 7:e017157-e017157. 2017
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 377:1319-1330. 2017
- Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF‐TIMI 48 Trial. Journal of the American Heart Association. 6:e006703. 2017
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine. 376:1527-1539. 2017
- Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 135:1273-1275. 2017
- Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 7:e014579-e014579. 2017
- Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 103:307-314. 2017
- Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 69:176-185. 2017
- Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 10:e004267. 2017
- Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 68:606-613. 2016
- Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. Stroke. 47:2075-2082. 2016
-
Cardioversion of Atrial Fibrillation in
ENGAGE AF‐TIMI 48. Clinical Cardiology. 39:345-346. 2016 - Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association. 5:e002197-e002197. 2016
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. The Lancet. 385:2067-2076. 2015
- Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation. Cardiovascular Quality and Outcomes. 8:S12-S20. 2015
- Interaction Between Digoxin and Dronedarone in the PALLAS Trial. Circulation: Arrhythmia and Electrophysiology. 7:1019-1025. 2014
- Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. Circulation. Heart Failure. 7:740-751. 2014
- Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. Stroke. 45:2372-2378. 2014
- A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia. Clinical Infectious Diseases. 59:51-61. 2014
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine. 369:2093-2104. 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine. 369:1327-1335. 2013
- Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. European Heart Journal. 34:3117-3127. 2013
- Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). International Journal of Cardiology. 168:2416-2422. 2013
- Management of acute coronary syndromes in developing countries: ACute Coronary Events—a multinational Survey of current management Strategies. American Heart Journal. 162:852-859.e22. 2011
- Ecocardiograma sob estresse com dobutamina em pacientes assintomáticos com regurgitação aórtica. Arquivos Brasileiros de Cardiologia. 93:53-58. 2009
- III Diretriz sobre tratamento do infarto agudo do miocárdio. Arquivos Brasileiros de Cardiologia. 83:1-86. 2004
- Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis. Journal of the American College of Cardiology. 43:393-401. 2004
- Risk factors for myocardial infarction in Brazil. American Heart Journal. 146:331-338. 2003
- Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. American Journal of Cardiology. 75:707-710. 1995
- [Noninvasive evaluation of ischemia and viability after acute myocardial infarction].. Arquivos Brasileiros de Cardiologia. 64:367-372. 1995
- 986-79 Identification of Coronary Artery Disease and Assessment of Prognosis in Patients with Chronic Renal Failure: Role of Dobutamine Stress Echocardiography. Journal of the American College of Cardiology. 25:306A-306A. 1995
- [Echocardiographic diagnosis of hematoma compressing the right atrium in post-operative heart surgery].. Arquivos Brasileiros de Cardiologia. 60:261-263. 1993
- A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Research. 5:117-117.
- A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol. Gates Open Research. 5:117-117.
-
preprints